-
Experts tend to focus on the kinds of foods you can eat to improve your health. But the speed at which you devour your dinner matters just as much.
-
Many employers and insurers are scaling back coverage and Medicare doesn’t cover the drugs for obesity. Meantime, some big employers are adding coverage, but their commitment isn’t guaranteed.
-
The AP-NORC survey shows about half of U.S. adults believe it is a good thing for adults to use Ozempic, Wegovy and similar GLP-1 drugs if they are struggling with weight. That support doesn't go for teens.
-
Will you still carry this added weight on New Year's Day 2026? For a quarter of us, that is probably going to prove true, according to a survey.
-
A new HHS rule would require Medicare and Medicaid to cover drugs like Wegovy or Zepbound for a large segment of Americans. But it’s unclear if it will will have support of the Trump administration.
-
Most people taking drugs like Ozempic and Wegovy have shed significant pounds. But obesity experts say that roughly 20% of patients — as many as 1 in 5 — may not see robust results with the medications.
-
After developing Type 2 diabetes and having a heart attack in his 40s, Clearwater resident Fabricio Zambrano switched to a plant-based lifestyle.
-
In a leadership shakeup, the diet company says CEO Sima Sistani would leave her role effective immediately. Tara Comonte, a board member and former Shake Shack exec, was named interim chief.
-
Cheaper versions of Wegovy and Zepbound touted on social media could be fleeting. Copies are legal now because the brand-name drugs are in short supply. But the drugmakers are boosting production.
-
New research shows that the number of 12- to 25-year-olds who used the GLP-1 medications climbed from about 8,700 a month in 2020 to 60,000 a month in 2023.